Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau Medical Ltd will host a conference call on May 11, 2026, at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for recurrent glioblastoma. The REGAIN trial aims to evaluate the feasibility and safety of Alpha DaRT in patients with recurrent glioblastoma who are not candidates for surgical resection.
Key figures
- Drug Name
- Alpha DaRT (®)
- Phase Of Trial
- Interim results from first three patients
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.